Zymeworks, Inc. (ZYME)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$29.19-2.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ZYME
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 37.1 | 106.0 | 76.3 | 76.0 | 412.5 | 26.7 | 39.0 |
| Operating Expenses & Income | |||||||
| R&D Expenses | — | — | — | 143.6 | 208.6 | 199.8 | 171.2 |
| Other Operating Expenses, Total | 4.2 | 12.8 | 20.5 | 18.8 | 4.7 | 3.3 | 7.3 |
| Operating Income | (155.6) | (92.5) | (137.1) | (138.1) | 130.5 | (215.6) | (187.5) |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | 0.3 | (0.6) | 0.6 | (0.9) | 1.1 | 1.3 | 1.6 |
| EBT, Incl. Unusual Items | (151.4) | (79.8) | (116.6) | (119.2) | 135.2 | (212.4) | (180.1) |
| Income Tax Expense | (1.4) | 1.4 | 6.1 | (0.6) | 10.9 | (0.5) | 0.4 |
| Net Income | |||||||
| Net Income | (150.0) | (81.1) | (122.7) | (118.7) | 124.3 | (211.8) | (180.6) |
| Per Share | |||||||
| Basic EPS | (2.05) | (1.08) | (1.62) | (1.72) | 1.91 | (4.11) | (3.58) |
| Diluted EPS | (2.05) | (1.08) | (1.62) | (1.72) | 1.90 | (4.61) | (3.58) |
| Revenue per Share | 0.51 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 73.0 | 75.4 | 75.8 | 68.9 | 65.2 | 51.6 | 50.4 |
| Diluted Weighted Avg Shares | 73.0 | 75.4 | 75.9 | 68.9 | 65.2 | 52.1 | 50.4 |
| Supplemental | |||||||
| EBIT | (155.6) | (92.5) | (137.1) | (138.1) | 130.5 | (215.6) | (187.5) |
| Effective Tax Rate | 0.9% | — | — | 0.5% | 8.1% | 0.2% | -0.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.